170876-51-4 Usage
Description
1-(3,4-difluorophenoxy)-2,3-epoxypropane, also known as epichlorohydrin difluorophenyl ether, is a colorless liquid chemical compound with the molecular formula C9H8F2O2. It is recognized for its reactivity, undergoing various chemical reactions such as nucleophilic substitution and epoxidation. Due to its toxicity and potential carcinogenic properties, it requires careful handling and adherence to safety regulations.
Uses
Used in Chemical Synthesis:
1-(3,4-difluorophenoxy)-2,3-epoxypropane is used as a building block in the chemical industry for the production of other chemicals. Its reactivity allows it to be a versatile component in the synthesis of a range of compounds.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 1-(3,4-difluorophenoxy)-2,3-epoxypropane is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure contributes to the development of new drugs.
Used in Agrochemical Production:
1-(3,4-difluorophenoxy)-2,3-epoxypropane is also utilized in the agrochemical sector, where it serves as a starting material for the creation of different agrochemicals that are used in the agricultural industry.
Used as a Solvent:
Due to its liquid state and chemical properties, 1-(3,4-difluorophenoxy)-2,3-epoxypropane is used as a solvent in various industrial processes. Its solvent properties make it suitable for dissolving and processing other substances in a controlled environment.
Safety and Handling:
Given its toxic nature and potential to cause irritation to the skin, eyes, and respiratory system, 1-(3,4-difluorophenoxy)-2,3-epoxypropane must be handled with care. It is classified as a potential carcinogen, and proper safety measures, including the use of personal protective equipment and adherence to disposal protocols, are essential to minimize health and environmental risks.
Check Digit Verification of cas no
The CAS Registry Mumber 170876-51-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,8,7 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 170876-51:
(8*1)+(7*7)+(6*0)+(5*8)+(4*7)+(3*6)+(2*5)+(1*1)=154
154 % 10 = 4
So 170876-51-4 is a valid CAS Registry Number.
170876-51-4Relevant articles and documents
Enantioselective transesterification of (RS)-1-chloro-3-(3,4-difluorophenoxy)-2-propanol using Pseudomonas aeruginosa lipases
Singh, Manpreet,Banerjee, Uttam Chand
, p. 2079 - 2085 (2007)
Lipases from the bacterial strain, Pseudomonas aeruginosa, isolated from the soil by enrichment techniques, are assessed for the enantioselective transesterification of (RS)-1-chloro-3-(3,4-difluorophenoxy)-2-propanol (rac-CDPP) to (R)-1-chloro-3-(3,4-dif
The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca2+/calmodulin-dependent kinase II
Bruno, Claudio,Cavalluzzi, Maria Maddalena,Rusciano, Maria Rosaria,Lovece, Angelo,Carrieri, Antonio,Pracella, Riccardo,Giannuzzi, Giulia,Polimeno, Lorenzo,Viale, Maurizio,Illario, Maddalena,Franchini, Carlo,Lentini, Giovanni
supporting information, p. 36 - 45 (2016/04/19)
An affinity capillary electrophoresis (ACE) method to estimate apparent dissociation constants between bovine brain calmodulin (CaM) and non-peptidic ligands was developed. The method was validated reproducing the dissociation constants of a number of wel
SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
-
Page/Page column 40, (2010/04/23)
The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
